{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:17:58Z","timestamp":1793459878938,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Social Science Foundation of China","award":["19AZD013"],"award-info":[{"award-number":["19AZD013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The diagnosis and health care of patients with rare diseases present a tremendous challenge worldwide. This study described the health care service utilization through participants\u2019 perspective and estimated the cost of illness (COI), and patients with Gaucher disease (GD)\u2019s\/caregivers\u2019 health-related quality of life in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>An online retrospective survey of patients with GD and their caregivers was conducted during May\u2013June 2018. Socio-demographic, health service utilization, disease-related expenses, social support, sleep quality (Pittsburgh Sleep Quality Index [PSQI]), and the Short Form Health Survey (SF-36) were investigated. Using self-reported information, we estimated the annual COI, including direct healthcare, direct non-healthcare, and indirect costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty patients and their 49 caregivers were surveyed. The patients\u2019 onset age of GD was 9.3\u2009\u00b1\u200910.9; their disease course was 3.5\u2009\u00b1\u20093.1\u00a0years. 21 (42.9%) patients had\u2009\u2265\u20092 caregivers, but 35 (71.4%) caregivers reported have no experience as a caregiver. 79.6% caregivers have stopped working, and 87.8% changed weekly working schedule. Before final diagnosis, patients visited 3.9\u2009\u00b1\u20093.1 (max\u2009=\u200920) hospitals and took 1.2\u2009\u00b1\u20091.7 (max\u2009=\u20096.6) years for confirmed diagnosis. On average, 5.0\u2009\u00b1\u20099.6 misdiagnoses occurred, and the per-patient diagnoses cost was USD ($) 7576. After GD confirmation, 8 (16.3%) patients received no treatment, 40 (81.6%) received pharmacotherapy, 10 (20.4%) received surgery, 38 (77.6%) received outpatient service (8.8\u2009\u00b1\u20099.1 times\/annually), and 37 (77.5%) received inpatient service (4.0\u2009\u00b1\u20093.5 times\/annually). Annual per-patient COI was USD ($) 49,925 (95% confidence interval: 29,178, 70,672). Average direct healthcare cost was $41,816, including pharmaceutical ($29,908), inpatient ($7,451), and outpatient ($1,838). Productivity loss per-caregiver was $1,980, and their Zarit Burden Inventory score was moderate-severe (48.6\u2009\u00b1\u200919.6). Both patients\/caregivers reported lower social support (32.4\u2009\u00b1\u20097.4, 34.9\u2009\u00b1\u20097.6), two times higher PSQI (7.9\u2009\u00b1\u20092.9, 8.7\u2009\u00b1\u20093.6), and half lower SF-36 (41.3\u2009\u00b1\u200918.6, 46.5\u2009\u00b1\u200919.3) than those reported for healthy Chinese individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The high misdiagnosis rate, together with delayed diagnosis, substantial costs, and deteriorated health-related quality of life of GD patients as well as their heavy care burden, calls for extreme attention from policymakers in China. Further efforts of government and society are urgently demanded, including pharmaceutical reimbursement, screening newborns, developing precise diagnostic tools, and training doctors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01963-6","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T07:10:28Z","timestamp":1628665828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Economic burden and health related quality of life of ultra-rare Gaucher disease in China"],"prefix":"10.1186","volume":"16","author":[{"given":"Xinye","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5266","authenticated-orcid":false,"given":"Qunhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40200-019-00399-x","volume":"18","author":"M Davari","year":"2019","unstructured":"Davari M, Nabizadeh A, Kadivar M, Asl AA, Sarkheil P. Healthcare resource utilization and cost of care for Gaucher patients in Iran. J Diabetes Metab Disord. 2019;18:127\u201332.","journal-title":"J Diabetes Metab Disord"},{"key":"1963_CR2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.3390\/jcm9082343","volume":"9","author":"C Serratrice","year":"2020","unstructured":"Serratrice C, Stirnemann J, Berrahal A, Belmatoug N, Camou F, Caillaud C, et al. A cross-sectional retrospective study of non-splenectomized and never-treated patients with type 1 gaucher disease. J Clin Med. 2020;9:2343.","journal-title":"J Clin Med"},{"key":"1963_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5582\/irdr.2019.01066","volume":"8","author":"J He","year":"2019","unstructured":"He J, Tang M, Zhang X, Chen D, Kang Q, Yang Y, et al. Incidence and prevalence of 121 rare diseases in China: current status and challenges. Intractable Rare Dis Res. 2019;8:89\u201397.","journal-title":"Intractable Rare Dis Res"},{"key":"1963_CR4","unstructured":"Yang Y, He J, Wang Y, Kang Q, Hu S. Study Feasibility of Multi-payment for Drugs for Rare Diseases\u2014Taking Gaucher\u2019s Disease in Qingdao as Example. China Pharm. 30:2593\u20136."},{"key":"1963_CR5","unstructured":"General Office. National Health Commission. Notice on publication of the Rare Diseases Diagnosis and Treatment Guide (2019) [Internet]. [cited 2020 Nov 19]. Available from: http:\/\/www.nhc.gov.cn\/yzygj\/s7659\/201902\/61d06b4916c348e0810ce1fceb844333.shtml"},{"key":"1963_CR6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/2008-132-851-GDROTL","volume":"132","author":"M Chen","year":"2008","unstructured":"Chen M, Wang J. Gaucher disease: review of the literature. Arch Pathol Lab Med. 2008;132:851\u20133.","journal-title":"Arch Pathol Lab Med"},{"key":"1963_CR7","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385:2355\u201362.","journal-title":"Lancet"},{"key":"1963_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13:107\u201318.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1963_CR9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13023-020-01544-z","volume":"15","author":"T Dinur","year":"2020","unstructured":"Dinur T, Istaiti M, Frydman D, Becker-Cohen M, Szer J, Zimran A, et al. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. Orphanet J Rare Dis. 2020;15:284.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/s12889-019-6952-5","volume":"19","author":"B \u0141yszczarz","year":"2019","unstructured":"\u0141yszczarz B. Indirect costs and incidence of caregivers\u2019 short-term absenteeism in Poland, 2006\u20132016. BMC Public Health. 2019;19:598.","journal-title":"BMC Public Health"},{"key":"1963_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327\u201337.","journal-title":"Clin Mol Hepatol"},{"key":"1963_CR12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13023-016-0454-7","volume":"11","author":"X-X Xin","year":"2016","unstructured":"Xin X-X, Guan X-D, Shi L-W. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China. Orphanet J Rare Dis. 2016;11:74.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13023-016-0392-4","volume":"11","author":"S Gong","year":"2016","unstructured":"Gong S, Wang Y, Pan X, Zhang L, Huang R, Chen X, et al. The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis. 2016;11:20.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR14","doi-asserted-by":"crossref","first-page":"A391","DOI":"10.1016\/j.jval.2014.08.858","volume":"17","author":"L Nalysnyk","year":"2014","unstructured":"Nalysnyk L, Hamed A, Hurwitz G, Simeone J, Rotella P. A Comprehensive literature review of the burden of Gaucher disease. Value Health. 2014;17:A391.","journal-title":"Value Health"},{"key":"1963_CR15","doi-asserted-by":"crossref","first-page":"e0204206","DOI":"10.1371\/journal.pone.0204206","volume":"13","author":"JC Hsu","year":"2018","unstructured":"Hsu JC, Wu H-C, Feng W-C, Chou C-H, Lai EC-C, Lu CY. Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan\u2019s National Health Insurance Research Database. PLoS ONE. 2018;13:e0204206.","journal-title":"PLoS ONE"},{"key":"1963_CR16","unstructured":"Statement for Rare Disease Day [Internet]. [cited 2020 Nov 28]. https:\/\/www.who.int\/news\/item\/27-02-2018-statement-for-rare-disease-day"},{"key":"1963_CR17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5582\/bst.2019.01209","volume":"13","author":"J He","year":"2019","unstructured":"He J, Song P, Kang Q, Zhang X, Hu J, Yang Y, et al. Overview on social security system of rare diseases in China. Biosci Trends. 2019;13:314\u201323.","journal-title":"Biosci Trends"},{"key":"1963_CR18","first-page":"224","volume":"68","author":"WR Evans","year":"2018","unstructured":"Evans WR. Dare to think rare: diagnostic delay and rare diseases. Br J Gen Pract. 2018;68:224\u20135.","journal-title":"Br J Gen Pract"},{"key":"1963_CR19","unstructured":"Accurate Diagnosis of Rare Diseases Remains Difficult Despite Strong Physician Interest [Internet]. Global Genes. 2014 [cited 2020 Dec 3]. https:\/\/globalgenes.org\/2014\/03\/06\/accurate-diagnosis-of-rare-diseases-remains-difficult-despite-strong-physician-interest\/"},{"key":"1963_CR20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ejh.12596","volume":"96","author":"I Motta","year":"2016","unstructured":"Motta I, Filocamo M, Poggiali E, Stroppiano M, Dragani A, Consonni D, et al. A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and\/or Thrombocytopenia. Eur J Haematol. 2016;96:352\u20139.","journal-title":"Eur J Haematol"},{"key":"1963_CR21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.vhri.2013.02.010","volume":"2","author":"B Tang","year":"2013","unstructured":"Tang B, Harary E, Kurzman R, Mould-Quevedo JF, Pan S, Yang J, et al. Clinical characterization and the caregiver burden of dementia in China. Value Health Reg Issues. 2013;2:118\u201326.","journal-title":"Value Health Reg Issues"},{"key":"1963_CR22","doi-asserted-by":"crossref","first-page":"e0228152","DOI":"10.1371\/journal.pone.0228152","volume":"15","author":"J Sun","year":"2020","unstructured":"Sun J, Sun R, Jiang Y, Chen X, Li Z, Ma Z, et al. The relationship between psychological health and social support: evidence from physicians in China. PLoS ONE. 2020;15:e0228152.","journal-title":"PLoS ONE"},{"key":"1963_CR23","unstructured":"Wang X, Wang X, Ma H. Manual of Mental Health Rating Scale (Updated Edition) [Internet]. Beijing: Chinese Journal of Mental Health; 1999 [cited 2020 Nov 20]. https:\/\/www.hanspub.org\/reference\/ReferencePapers.aspx?ReferenceID=87567"},{"key":"1963_CR24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jech.57.4.259","volume":"57","author":"L Li","year":"2003","unstructured":"Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health. 2003;57:259\u201363.","journal-title":"J Epidemiol Community Health"},{"key":"1963_CR25","unstructured":"Pierre-Etienne C, Anne-Sophie C, S\u00e9gol\u00e8ne A, Christian D. Diagnostic delay in rare diseases: a documented list of (296) rare diseases for which delayed diagnosis would be especially detrimental, based on the French situation. 2020 [cited 2020 Nov 27]; https:\/\/www.researchsquare.com\/article\/rs-32308\/v1"},{"key":"1963_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-017-0627-z","volume":"12","author":"M Andrade-Campos","year":"2017","unstructured":"Andrade-Campos M, Alfonso P, Irun P, Armstrong J, Calvo C, Dalmau J, et al. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. Orphanet J Rare Dis. 2017;12:84.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR27","unstructured":"Experiences of Rare Diseases: An Insight from Patients and Families (2010) [Internet]. Rare Disease UK; 2010 Dec p. 37. Available from: https:\/\/www.raredisease.org.uk\/our-work\/experiences-of-rare-diseases-an-insight-from-patients-and-families-2010\/"},{"key":"1963_CR28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcmd.2012.11.004","volume":"50","author":"AS Thomas","year":"2013","unstructured":"Thomas AS, Mehta AB, Hughes DA. Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 2013;50:212\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"1963_CR29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists - oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697\u2013701.","journal-title":"Am J Hematol"},{"key":"1963_CR30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-8-22","volume":"8","author":"M Anderson","year":"2013","unstructured":"Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis. 2013;8:22.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13023-015-0333-7","volume":"10","author":"M Chopra","year":"2015","unstructured":"Chopra M, Duan T. Rare genetic disease in China: a call to improve clinical services. Orphanet J Rare Dis. 2015;10:140.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR32","doi-asserted-by":"publisher","unstructured":"Xuefeng L, Xiangyu Z, Shu Z, Zijuan L, Jianyong Z, Jincheng Z, et al. Rare disease awareness and perspectives of physicians in China: a questionnaire -based study. 2020 [cited 2020 Dec 5]; https:\/\/doi.org\/10.21203\/rs.3.rs-65651\/v1","DOI":"10.21203\/rs.3.rs-65651\/v1"},{"key":"1963_CR33","unstructured":"Pomeranz K. EvaluatePharma\u00ae Orphan Drug Report 2019.pdf [Internet]. April p. 30. https:\/\/info.evaluate.com\/rs\/607-YGS-364\/images\/EvaluatePharma%20Orphan%20Drug%20Report%202019.pdf"},{"key":"1963_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5246\/jcps.2018.05.037","volume":"27","author":"F Mengyuan","year":"2018","unstructured":"Mengyuan F, Xiaodong G, Guoxu W, Xiaoxiong X, Luwen S. Medical service utilisation, economic burden and health status of patients with rare diseases in China. J Chin Pharm. 2018;27:361\u20139.","journal-title":"J Chin Pharm"},{"key":"1963_CR35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-019-1075-8","volume":"14","author":"L Vandeborne","year":"2019","unstructured":"Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire -based study in Belgium. Orphanet J Rare Dis. 2019;14:99.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3654","volume":"11","author":"I Melnikova","year":"2012","unstructured":"Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discovery. 2012;11:267\u20138.","journal-title":"Nat Rev Drug Discovery"},{"key":"1963_CR37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13023-017-0622-4","volume":"12","author":"Y Zurynski","year":"2017","unstructured":"Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12:68.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-017-0733-y","volume":"13","author":"G-A Kuiper","year":"2018","unstructured":"Kuiper G-A, Meijer OLM, Langereis EJ, Wijburg FA. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet J Rare Dis. 2018;13:2.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cca.2020.03.016","volume":"506","author":"Y Huang","year":"2020","unstructured":"Huang Y, Jia X, Tang C, Liu S, Sheng H, Zhao X, et al. High risk screening for Gaucher disease in patients with splenomegaly and\/or thrombocytopenia in China: 55 cases identified. Clin Chim Acta. 2020;506:22\u20137.","journal-title":"Clin Chim Acta"},{"key":"1963_CR40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-018-0782-x","volume":"13","author":"K Lei","year":"2018","unstructured":"Lei K, Zhao Y, Sun L, Liang H, Luo R, Sun X, et al. A pilot screening of high-risk Gaucher disease children using dried blood spot methods in Shandong province of China. Orphanet J Rare Dis. 2018;13:48.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","volume":"122","author":"A Mehta","year":"2017","unstructured":"Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, G\u00f6ker-Alpan \u00d6, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122:122\u20139.","journal-title":"Mol Genet Metab"},{"key":"1963_CR42","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/imj.14156","volume":"49","author":"A Mehta","year":"2019","unstructured":"Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J. 2019;49:578\u201391.","journal-title":"Intern Med J"},{"key":"1963_CR43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","volume":"172","author":"P Kaplan","year":"2013","unstructured":"Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013;172:447\u201358.","journal-title":"Eur J Pediatr"},{"key":"1963_CR44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13023-014-0112-x","volume":"9","author":"L van Dussen","year":"2014","unstructured":"van Dussen L, Biegstraaten M, Dijkgraaf MG, Hollak CE. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis. 2014;9:112.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","volume":"93","author":"A Zimran","year":"2018","unstructured":"Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D, et al. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher Outcome Survey (GOS). Am J Hematol. 2018;93:205\u201312.","journal-title":"Am J Hematol"},{"key":"1963_CR46","doi-asserted-by":"publisher","unstructured":"Dinur T, Zimran A, Becker-Cohen M, Arkadir D, Cozma C, Hovakimyan M, et al. Long term follow-up of 103 untreated adult patients with Type 1 Gaucher disease. J Clin Med [Internet]. 2019;8. https:\/\/doi.org\/10.3390\/jcm8101662","DOI":"10.3390\/jcm8101662"},{"key":"1963_CR47","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/03007990902892633","volume":"25","author":"M Schlander","year":"2009","unstructured":"Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009;25:1285\u201393.","journal-title":"Curr Med Res Opin"},{"key":"1963_CR48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1005655031239","volume":"23","author":"P Maaswinkel-Mooij","year":"2000","unstructured":"Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, P\u00f6ll R. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis. 2000;23:77\u201382.","journal-title":"J Inherit Metab Dis"},{"key":"1963_CR49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcmd.2016.10.002","volume":"68","author":"NJ Weinreb","year":"2018","unstructured":"Weinreb NJ, Barbouth DS, Lee RE. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells Mol Dis. 2018;68:211\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"1963_CR50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","volume":"151","author":"G Drelichman","year":"2007","unstructured":"Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr. 2007;151:197\u2013201.","journal-title":"J Pediatr"},{"key":"1963_CR51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-020-01520-7","volume":"15","author":"MM Andrade-Campos","year":"2020","unstructured":"Andrade-Campos MM, de Frutos LL, Cebolla JJ, Serrano-Gonzalo I, Medrano-Engay B, Roca-Espiau M, et al. Identification of risk features for complication in Gaucher\u2019s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 2020;15:256.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR52","first-page":"11","volume":"55","author":"RD Puri","year":"2018","unstructured":"Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, et al. Diagnosis and Management of Gaucher Disease in India\u2014consensus guidelines of the Gaucher disease task force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018;55:11.","journal-title":"Indian Pediatr"},{"key":"1963_CR53","unstructured":"National Data [Internet]. [cited 2020 Nov 17]. Available from: https:\/\/data.stats.gov.cn\/english\/"},{"key":"1963_CR54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-9-51","volume":"9","author":"L van Dussen","year":"2014","unstructured":"van Dussen L, Biegstraaten M, Hollak CEM, Dijkgraaf MGW. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014;9:51.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR55","unstructured":"Statistical Bulletin of China\u2019s Health Development (2018) [Internet]. [cited 2020 Nov 18]. http:\/\/www.nhc.gov.cn\/guihuaxxs\/s10748\/201905\/9b8d52727cf346049de8acce25ffcbd0.shtml"},{"key":"1963_CR56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13023-019-1168-4","volume":"14","author":"X Cai","year":"2019","unstructured":"Cai X, Yang H, Genchev GZ, Lu H, Yu G. Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai. Orphanet J Rare Dis. 2019;14:233.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR57","unstructured":"WHO | Negotiating prices of drugs for rare diseases [Internet]. WHO. [cited 2020 Dec 4]. http:\/\/www.who.int\/bulletin\/volumes\/94\/10\/15-163519\/en\/"},{"key":"1963_CR58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5582\/irdr.2019.01068","volume":"8","author":"Y Yang","year":"2019","unstructured":"Yang Y, Kang Q, Hu J, Kong F, Tang M, He J, et al. Accessibility of drugs for rare diseases in China: policies and current situation. Intractable Rare Dis Res. 2019;8:80\u20138.","journal-title":"Intractable Rare Dis Res"},{"key":"1963_CR59","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.xphs.2019.01.012","volume":"108","author":"X Guan","year":"2019","unstructured":"Guan X, Zhang J, Man C, Ni B, Shi L. How far have we come? Challenges to orphan drug access in China, 2011\u20132017. J Pharm Sci. 2019;108:2199\u2013205.","journal-title":"J Pharm Sci"},{"key":"1963_CR60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5582\/irdr.2018.01056","volume":"7","author":"J He","year":"2018","unstructured":"He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intract Rare Dis Res. 2018;7:145\u20137.","journal-title":"Intract Rare Dis Res"},{"key":"1963_CR61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13023-017-0568-6","volume":"12","author":"A Cheng","year":"2017","unstructured":"Cheng A, Xie Z. Challenges in orphan drug development and regulatory policy in China. Orphanet J Rare Dis. 2017;12:13.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR62","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(16)30418-4","volume":"387","author":"D Dong","year":"2016","unstructured":"Dong D, Wang Y. Challenges of rare diseases in China. Lancet. 2016;387:1906.","journal-title":"Lancet"},{"key":"1963_CR63","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2214-109X(16)00041-3","volume":"4","author":"X Guan","year":"2016","unstructured":"Guan X, Qi L, Liu L. Controversy in public hospital reforms in China. Lancet Global Health. 2016;4:e240.","journal-title":"Lancet Global Health"},{"key":"1963_CR64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-9-62","volume":"9","author":"E Picavet","year":"2014","unstructured":"Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62.","journal-title":"Orphanet J Rare Dis"},{"key":"1963_CR65","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/bmj.331.7523.1016","volume":"331","author":"C McCabe","year":"2005","unstructured":"McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016\u20139.","journal-title":"BMJ"},{"key":"1963_CR66","unstructured":"Huang R, Shao W. China Rare Disease Drug Accessibility Report [Internet]. Chinese Organization for Rase Disorders; 2019 p. 75. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/china\/viewpoints\/viewpoint-issue-42.pdf"},{"key":"1963_CR67","doi-asserted-by":"crossref","unstructured":"Lucas F. Improving market access to rare disease therapies: a worldwide perspective with recommendations to the industry. Medicine Access @ Point of Care. 2018;2:2399202618810121.","DOI":"10.1177\/2399202618810121"},{"key":"1963_CR68","doi-asserted-by":"crossref","first-page":"A883","DOI":"10.1016\/j.jval.2016.08.295","volume":"19","author":"H Shi","year":"2016","unstructured":"Shi H, Huang L, Xu L. Current situation and prospect of orphan drugs in China. Value Health. 2016;19:A883.","journal-title":"Value Health"},{"key":"1963_CR69","doi-asserted-by":"crossref","unstructured":"GPhA Report: Savings: $1 trillion over 10 years\u2014generic drug savings in the US. J Pharmaceut Health Serv Res 2012;3:229\u201336.","DOI":"10.1111\/jphs.12000"},{"key":"1963_CR70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7175\/fe.v13i3S.312","volume":"13","author":"B Godman","year":"2012","unstructured":"Godman B, Bennie M, Baumg\u00e4rtel C, Sovi\u0107-Brki\u010di\u0107 L, Burkhardt T, F\u00fcrst J, et al. Essential to increase the use of generics in Europe to maintain comprehensive health care? Farmeconomia Health Econ Therap Pathways. 2012;13:5\u201320.","journal-title":"Farmeconomia Health Econ Therap Pathways"},{"key":"1963_CR71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1008859420641","volume":"8","author":"BJ Masek","year":"1999","unstructured":"Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999;8:263\u20138.","journal-title":"Qual Life Res"},{"key":"1963_CR72","unstructured":"Gengchun C. Optimizing the terms of mental health check about adults in city of our country\u2014study on the degree of social support. J Xi\u2019an Inst Phys Educ; 18:99\u2013101"},{"key":"1963_CR73","first-page":"103","volume":"29","author":"L Xianchen","year":"1996","unstructured":"Xianchen L, Maoqin T, Lei H, Aizhen W, HongXin W, Guifang Z, et al. Reliability and validity of the Pittsburgh sleep quality index. Chin J Psychiatry. 1996;29:103\u20137.","journal-title":"Chin J Psychiatry"},{"key":"1963_CR74","first-page":"636","volume":"31","author":"P Yanfang","year":"2011","unstructured":"Yanfang P, Chaozeng S, Huiqian H, Bin W, Guang L. Survey of health-related quality of life in population of 6 Chinese cities. Basic Clin Med. 2011;31:636\u201341.","journal-title":"Basic Clin Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01963-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01963-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01963-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T22:50:15Z","timestamp":1673045415000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01963-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01963-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-127301\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"6 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Harbin Medical University (No.HMUIRB20200001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"358"}}